

CDKN1A RABBIT PAB

Cat.#: S216264

Product Name: Anti-CDKN1A Rabbit Polyclonal Antibody

Synonyms: P21; CIP1; SDI1; WAF1; CAP20; CDKN1; MDA-6; p21CIP1

UNIPROT ID: P38936 (Gene Accession - BC000275)

Background: This gene encodes a potent cyclin-dependent kinase inhibitor. The encoded protein binds to and inhibits the activity of cyclin-CDK2 or -CDK4 complexes, and thus functions as a regulator of cell cycle progression at G1. The expression of this gene is tightly controlled by the tumor suppressor protein p53, through which this protein mediates the p53-dependent cell cycle G1 phase arrest in response to a variety of stress stimuli. This protein can interact with proliferating cell nuclear antigen (PCNA), a DNA polymerase accessory factor, and plays a regulatory role in S phase DNA replication and DNA damage repair. This protein was reported to be specifically cleaved by CASP3-like caspases, which thus leads to a dramatic activation of CDK2, and may be instrumental in the execution of apoptosis following caspase activation. Multiple alternatively spliced variants have been found for this gene.

Immunogen: Fusion protein of human CDKN1A

Applications: ELISA, IHC

Recommended Dilutions: IHC: 25-100; ELISA: 2000-5000

Host Species: Rabbit

Clonality: Rabbit Polyclonal

Isotype: Immunogen-specific rabbit IgG


Purification: Antigen affinity purification

Species Reactivity: Human


Constituents: PBS (without Mg²⁺ and Ca²⁺), pH 7.4, 150 mM NaCl, 0.05% Sodium Azide and 40% glycerol

Research Areas: Epigenetics and Nuclear Signaling, Cancer

Storage & Shipping: Store at -20°C. Avoid repeated freezing and thawing



Immunohistochemistry analysis of paraffin embedded Human breast cancer tissue using 216264(CDKN1A Antibody) at a dilution of 1/30(Nucleus).



In comparison with the IHC on the left, the same paraffin-embedded Human breast cancer tissue is first treated with the fusion protein and then with 216264(Anti-CDKN1A Antibody) at dilution 1/30.



Product Description

Pioneering GTPase and Oncogene Product Development since 2010
